These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 36656084)

  • 21. Insights into high affinity small ubiquitin-like modifier (SUMO) recognition by SUMO-interacting motifs (SIMs) revealed by a combination of NMR and peptide array analysis.
    Namanja AT; Li YJ; Su Y; Wong S; Lu J; Colson LT; Wu C; Li SS; Chen Y
    J Biol Chem; 2012 Jan; 287(5):3231-40. PubMed ID: 22147707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determinants of small ubiquitin-like modifier 1 (SUMO1) protein specificity, E3 ligase, and SUMO-RanGAP1 binding activities of nucleoporin RanBP2.
    Gareau JR; Reverter D; Lima CD
    J Biol Chem; 2012 Feb; 287(7):4740-51. PubMed ID: 22194619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SUMO deconjugation is required for arsenic-triggered ubiquitylation of PML.
    Fasci D; Anania VG; Lill JR; Salvesen GS
    Sci Signal; 2015 Jun; 8(380):ra56. PubMed ID: 26060329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isoform-specific monobody inhibitors of small ubiquitin-related modifiers engineered using structure-guided library design.
    Gilbreth RN; Truong K; Madu I; Koide A; Wojcik JB; Li NS; Piccirilli JA; Chen Y; Koide S
    Proc Natl Acad Sci U S A; 2011 May; 108(19):7751-6. PubMed ID: 21518904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SUMO-specific protease 1 (SENP1) reverses the hormone-augmented SUMOylation of androgen receptor and modulates gene responses in prostate cancer cells.
    Kaikkonen S; Jääskeläinen T; Karvonen U; Rytinki MM; Makkonen H; Gioeli D; Paschal BM; Palvimo JJ
    Mol Endocrinol; 2009 Mar; 23(3):292-307. PubMed ID: 19116244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural Basis for the SUMO2 Isoform Specificity of SENP7.
    Li Y; De Bolòs A; Amador V; Reverter D
    J Mol Biol; 2022 Dec; 434(24):167875. PubMed ID: 36334780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aberrant SUMO2/3 modification of RUNX1 upon SENP1 inhibition is linked to the development of diabetic retinopathy in mice.
    Zhang W; Li F; Hou J; Cheng Y; Zhang W; Liang X; Wang J
    Exp Eye Res; 2023 Dec; 237():109695. PubMed ID: 37890757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conformational flexibility and changes underlying activation of the SUMO-specific protease SENP1 by remote substrate binding.
    Chen CH; Namanja AT; Chen Y
    Nat Commun; 2014 Sep; 5():4968. PubMed ID: 25263960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human SUMO fusion systems enhance protein expression and solubility.
    Wang Z; Li H; Guan W; Ling H; Wang Z; Mu T; Shuler FD; Fang X
    Protein Expr Purif; 2010 Oct; 73(2):203-8. PubMed ID: 20457256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SUMOylation regulates insulin exocytosis downstream of secretory granule docking in rodents and humans.
    Dai XQ; Plummer G; Casimir M; Kang Y; Hajmrle C; Gaisano HY; Manning Fox JE; MacDonald PE
    Diabetes; 2011 Mar; 60(3):838-47. PubMed ID: 21266332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spatiotemporal distribution of SUMOylation components during mouse brain development.
    Hasegawa Y; Yoshida D; Nakamura Y; Sakakibara S
    J Comp Neurol; 2014 Sep; 522(13):3020-36. PubMed ID: 24639124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Specification of SUMO1- and SUMO2-interacting motifs.
    Hecker CM; Rabiller M; Haglund K; Bayer P; Dikic I
    J Biol Chem; 2006 Jun; 281(23):16117-27. PubMed ID: 16524884
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SUMOylation protects against IL-1β-induced apoptosis in INS-1 832/13 cells and human islets.
    Hajmrle C; Ferdaoussi M; Plummer G; Spigelman AF; Lai K; Manning Fox JE; MacDonald PE
    Am J Physiol Endocrinol Metab; 2014 Oct; 307(8):E664-73. PubMed ID: 25139051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanism and consequences for paralog-specific sumoylation of ubiquitin-specific protease 25.
    Meulmeester E; Kunze M; Hsiao HH; Urlaub H; Melchior F
    Mol Cell; 2008 Jun; 30(5):610-9. PubMed ID: 18538659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SUMO1 modification of 0N4R-tau is regulated by PIASx, SENP1, SENP2, and TRIM11.
    Wada H; Maruyama T; Niikura T
    Biochem Biophys Rep; 2024 Sep; 39():101800. PubMed ID: 39286522
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the activity and substrate specificity of the human SENP family of SUMO proteases.
    Mendes AV; Grou CP; Azevedo JE; Pinto MP
    Biochim Biophys Acta; 2016 Jan; 1863(1):139-47. PubMed ID: 26522917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experimental comparison of energy landscape features of ubiquitin family proteins.
    Nandi T; Yadav A; Ainavarapu SRK
    Proteins; 2020 Mar; 88(3):449-461. PubMed ID: 31587348
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SUMO paralogue-specific functions revealed through systematic analysis of human knockout cell lines and gene expression data.
    Bouchard D; Wang W; Yang WC; He S; Garcia A; Matunis MJ
    Mol Biol Cell; 2021 Sep; 32(19):1849-1866. PubMed ID: 34232706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [SENP1 induced protein deSUMO modification increased the chemotherapy sensitivity of endometrial cancer side population cells].
    Yuan ML; Bai J; Li CY; Xue N; Chen XH; Sheng F; Liu XZ; Li P
    Zhonghua Zhong Liu Za Zhi; 2022 Dec; 44(12):1362-1368. PubMed ID: 36575788
    [No Abstract]   [Full Text] [Related]  

  • 40. Arkadia/RNF111 is a SUMO-targeted ubiquitin ligase with preference for substrates marked with SUMO1-capped SUMO2/3 chain.
    Sriramachandran AM; Meyer-Teschendorf K; Pabst S; Ulrich HD; Gehring NH; Hofmann K; Praefcke GJK; Dohmen RJ
    Nat Commun; 2019 Aug; 10(1):3678. PubMed ID: 31417085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.